Insider Buying: VBI Vaccines, Inc. (VBIV) CEO Purchases 10,000 Shares of Stock
VBI Vaccines, Inc. (NASDAQ:VBIV) CEO Jeff Baxter purchased 10,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $3.28 per share, with a total value of $32,800.00. Following the completion of the transaction, the chief executive officer now owns 110,255 shares of the company’s stock, valued at $361,636.40. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
VBI Vaccines, Inc. (NASDAQ VBIV) traded up 6.36% on Monday, hitting $3.68. The stock had a trading volume of 87,059 shares. The company’s 50-day moving average price is $4.37 and its 200 day moving average price is $4.61. The firm’s market cap is $148.04 million. VBI Vaccines, Inc. has a one year low of $2.75 and a one year high of $6.60.
TRADEMARK VIOLATION WARNING: “Insider Buying: VBI Vaccines, Inc. (VBIV) CEO Purchases 10,000 Shares of Stock” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/insider-buying-vbi-vaccines-inc-vbiv-ceo-purchases-10000-shares-of-stock/1488175.html.
Several research analysts have recently commented on VBIV shares. Zacks Investment Research lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Noble Financial restated a “buy” rating on shares of VBI Vaccines in a research report on Monday, July 31st. TheStreet lowered VBI Vaccines from a “c-” rating to a “d+” rating in a research report on Wednesday, May 31st. Finally, ValuEngine lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $5.38.
Hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its stake in VBI Vaccines by 8.6% in the second quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 5,000 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in VBI Vaccines during the second quarter worth approximately $187,000. Bank of New York Mellon Corp purchased a new stake in VBI Vaccines during the second quarter worth approximately $193,000. Teachers Advisors LLC purchased a new stake in VBI Vaccines during the second quarter worth approximately $195,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in VBI Vaccines during the second quarter worth approximately $262,000. Institutional investors and hedge funds own 29.49% of the company’s stock.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.